Updated study results of pelcitoclax (APG-1252) in combination with osimertinib in patients (pts) with EGFR-mutant non–small cell lung cancer (NSCLC)
Home » Updated study results of pelcitoclax (APG-1252) in combination with osimertinib in patients (pts) with EGFR-mutant non–small cell lung cancer (NSCLC)
2022
Zhang L, Zhao H, Zhao Y, Cheng Y, Cui J, Ma Y, Yang C, Zhang J, Xu L, Yu J, Men L, Liang Z, Yang D, Zhai Y. Updated study results of pelcitoclax (APG-1252) in combination with osimertinib in patients (pts) with EGFR-mutant non–small cell lung cancer (NSCLC). J Clin Oncol. [Poster presented at: 2022 ASCO Annual Meeting; June 3-7, 2022; Chicago, IL]. vol. 40 no. (suppl 16):, pp. 9116-9116, doi: 10.1200/JCO.2022.40.16_suppl.9116